Sign Out
Single doses of NGENLA higher than 0.66 mg/kg/wk have not been studied.
Based on experience with daily growth hormone products, short-term overdosage could lead initially to hypoglycemia and subsequently to hyperglycemia. Long-term overdosage could result in signs and symptoms of gigantism and/or acromegaly consistent with the effects of growth hormone excess.
There is no experience of overdose with NGENLA. Treatment of overdose with NGENLA should consist of general supportive measures.
Continue with Google